SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants
Autor: | Carlo Contini, Nicole Barp, John Charles Rotondo, Chiara Mazziotta, Altea Gallerani, Fernanda Martini, Giulia Di Mauro, Martina Maritati, Mauro Tognon, Carmen Lanzillotti |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Gene Expression Regulation
Viral medicine.medical_specialty COVID-19 Vaccines viruses CoV coronaviruses Review Genome Viral Biology spike protein medicine.disease_cause Viral Zoonoses Microbiology NO Viral vector Structure-Activity Relationship Viral Proteins coronavirus disease 2019 vaccine Virology Pandemic medicine Animals Humans Severe acute respiratory syndrome coronavirus 2 Phylogeny Coronavirus variants Transmission (medicine) SARS-CoV-2 Public health Zoonosis Disease Management COVID-19 Genomics zoonosis medicine.disease QR1-502 Vaccination Infectious Diseases Immunization Host-Pathogen Interactions Spike Glycoprotein Coronavirus Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 CoV coronaviruses coronavirus disease 2019 COVID-19 spike protein variants vaccine zoonosis Cytokine Release Syndrome |
Zdroj: | Viruses, Vol 13, Iss 1687, p 1687 (2021) Viruses |
ISSN: | 1999-4915 |
Popis: | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered coronavirus responsible for the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 has rapidly become a public health emergency of international concern. Although remarkable scientific achievements have been reached since the beginning of the pandemic, the knowledge behind this novel coronavirus, in terms of molecular and pathogenic characteristics and zoonotic potential, is still relatively limited. Today, there is a vaccine, or rather several vaccines, which, for the first time in the history of highly contagious infectious diseases that have plagued mankind, has been manufactured in just one year. Currently, four vaccines are licensed by regulatory agencies, and they use RNA or viral vector technologies. The positive effects of the vaccination campaign are being felt in many parts of the world, but the disappearance of this new infection is still far from being a reality, as it is also threatened by the presence of novel SARS-CoV-2 variants that could undermine the effectiveness of the vaccine, hampering the immunization control efforts. Indeed, the current findings indicate that SARS-CoV-2 is adapting to transmission in humans more efficiently, while further divergence from the initial archetype should be considered. In this review, we aimed to provide a collection of the current knowledge regarding the molecular, phylogenetic, and pathogenetic insights into SARS-CoV-2. The most recent findings obtained with respect to the impact of novel emerging SARS-CoV-2 variants as well as the development and implementation of vaccines are highlighted. |
Databáze: | OpenAIRE |
Externí odkaz: |